Cancer News: Kidney
Sunitinib can increase disease-free survival as adjuvant treatment for renal cell carcinoma after nephrectomy.
Cytoreductive surgery with targeted therapy improves survival rates in metastatic renal cell cancer patients.
Patients with advanced non-clear cell renal cell carcinoma (ncRCC) benefited from the combination treatment of everolimus and bevacizumab, researchers report.
A study reveals that some adult advanced kidney cancer patients may safely opt for an active surveillance scheme instead of aggressive treatments.
Lenvatinib combined with everolimus received a positive opinion by the EU regulator for the treatment of adult patients with advanced renal cell carcinoma.
Removing with surgery a cancerous kidney helped metastatic kidney cancer patients live longer, a new study reveals.
Advanced kidney cancer patients treated after disease progression with immunotherapy nivolumab survived longer, a new phase 3 study shows.
The combination of lenvatinib and everolimus received FDA approval for the treatment of advanced renal cell carcinoma following prior anti-angiogenetic therapy.
EU regulators have approved nivolumab as a treatment against advanced or metastatic non-squamous non-small cell lung cancer and advanced renal cell carcinoma.
A new study comparing the current standard care for renal cell carcinoma, everolimus and cabozantinib reveals the increased benefit of cabozantinib.
U.S. regulators approved Bristol-Myers Squibb's immunotherapy drug Opdivo for the treatment of patients with advanced (metastatic) renal cell carcinoma.
Patients of renal cell carcinoma benefited significantly when treated with a combination of lenvatinib with everolimus, a new phase 2 study reveals.
The targeted drug nivolumab extended survival in patients with advanced kidney cancer whose disease has progressed on prior treatment, according to a new study.
The immunotherapy drug Opdivo extended survival rates in kidney cancer patients by more than two years, a new study reports.
The results of two phase 3 clinical trials on metastatic renal cell carcinoma showed that patients benefited from two immunotherapeutic agents, nivolumab and cabozantinib.
Renal cell carcinoma patients treated with the combined therapy of lenvatinib with everolimus survived longer without disease progression, a new study reveals.
Patients with gastrointestinal stromal tumors may develop additional malignancies before and after their diagnosis, according to the first population-based study.
Clinical findings indicate that widely used treatments of metastatic kidney cancer, sorafenib and sunitinib, had similar disease recurrence results with placebo.
Adult survivors of childhood cancers who underwent certain chemotherapy treatments or kidney surgery had worse kidney function that did not recover over time. Because of this, they may be at higher risk for premature renal failure, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Examining 12 major types of cancer, scientists at Washington University School of Medicine in St. Louis have identified 127 repeatedly mutated genes that appear to drive the development and progression of a range of tumors in the body. The discovery sets the stage for devising new diagnostic tools and more personalized cancer treatments.
Researchers have identified four factors that are associated with survival time in patients who undergo metastasectomy for metastatic renal cell carcinoma (mRCC).
Tumor grade and stage have emerged as the most important predictors of mortality in a competing risks analysis of patients undergoing nephrectomy for renal cell carcinoma (RCC).
Results from a recent preclinical study have shown that a new drug combination therapy being developed effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells. The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients.
Targeted therapy efficacy in metastatic Renal Cell Carcinoma (RCC) predicted by early tumor shrinkage
Metastatic renal cell carcinoma (mRCC) tumor shrinkage after targeted therapy may prolong long-term survival for this type of kidney cancer, research shows.
Patients treated for kidney cancer with robot-assisted partial nephrectomy & have chronic kidney disease preserved kidney function, even better than those without chronic kidney disease.
Renal cell carcinoma (RCC) advances require more emphasis on molecular biology and genetics, according to a researcher at the Genitourinary Cancers Symposium.
Younger renal cancer patients with localized disease may benefit more from partial nephrectomy compared with complete removal of the kidney, researchers found.
A study found that patients with metastatic kidney cancer can tolerate and benefit from a treatment called high-dose interleukin-2 (HDIL-2) immunotherapy.
A large study showed that for kidney cancer patients, surgery and less radical, needle-guided procedures offer near equivalent cancer control for small tumors.